Opioid-Induced Constipation Treatment Market Report for M&A, Expansion and Competitive Benchmarking (2025–2034)
Unlock 30% off global market reports with code ONLINE30 – get insights on tariff changes, macro trends, and global economic shifts.
What is the anticipated market size of the opioid-induced constipation treatment industry over the next few years?
The opioid-induced constipation treatment market size has grown strongly in recent years. It will grow from $1.78 billion in 2024 to $1.9 billion in 2025 at a compound annual growth rate (CAGR) of 7.0%. The growth in the historic period can be attributed to expanding geriatric population, personalized OIC treatments, availability of effective OIC drugs, increasing prevalence of opioid use, and rising prevalence of gastrointestinal disorders.
The opioid-induced constipation treatment market size is expected to see strong growth in the next few years. It will grow to $2.47 billion in 2029 at a compound annual growth rate (CAGR) of 6.7%. The growth in the forecast period can be attributed to accelerated drug approval initiatives, increasing use of opioid analgesic prescriptions, surging expenditure on the R And D of novel treatments, and an increase in development of biologics. Major trends in the forecast period include patient education and awareness, the emergence of targeted therapies, non-pharmacological interventions, biotechnology innovations, and increased investment.
Download Your Free Sample PDF:
What emerging drivers are expected to shape the future of the opioid-induced constipation treatment market?
The rise in the administration of opioids for cancer and non-cancer pain is expected to propel the growth of the opioid-induced constipation treatment market going forward. Cancer pain refers to pain associated with cancer and its treatment, while non-cancer pain refers to pain from conditions unrelated to cancer. Administration of opioids for cancer and non-cancer pain is driven by the need to effectively manage moderate to severe pain, considering factors such as the intensity and duration of pain, patient response to other treatments, and the overall goal of improving quality of life while minimizing potential risks of addiction and side effects. Opioid-induced constipation (OIC) treatment helps patients with cancer and non-cancer pain by relieving constipation caused by opioid use, thereby improving overall comfort, adherence to pain management regimens, and quality of life without compromising pain relief. For instance, in May 2021, according to the Government of Canada, a Canada-based federal administration, up to 8.3 million Canadians may experience chronic pain by 2025, and it is expected to reach up to 9.0 million by 2030. Therefore, the rise in the administration of opioids for cancer and non-cancer pain is driving the growth of the opioid-induced constipation treatment market.
What emerging segments are shaping the future landscape of the opioid-induced constipation treatment industry?
The opioid-induced constipation treatment market covered in this report is segmented –
1) By Drug Class: Laxatives, Peripherally Acting µ-opioid Receptor Antagonists, Serotonin Receptor Agonists, Prostaglandin
2) By Type: Oral, Parenteral
3) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies
Subsegments:
1) By Laxatives: Osmotic Laxatives, Stimulant Laxatives, Bulk-Forming Laxatives
2) By Peripherally Acting µ-Opioid Receptor Antagonists: Naloxegol, Methylnaltrexone, Alvimopan
3) By Serotonin Receptor Agonists: Prucalopride, Tegaserod
4) By Prostaglandin: Lubiprostone
View The Full Market Report:
What are the key trends shaping the opioid-induced constipation treatment market in the forecast period?
Major companies operating in the opioid-induced constipation treatment market are adopting strategic partnerships approach to develop innovative medicines. Strategic partnerships help opioid-induced constipation treatment companies by combining resources and expertise, enhancing research and development capabilities, expanding market reach, and accelerating commercialization, ultimately driving innovation and growth in the opioid-induced constipation treatment industry. For instance, in November 2022, Kyowa Kirin Co. Ltd, a Japan-based biotechnology company, partnered with Grünenthal GmbH, Germany-based pharmaceutical company to integrate the solutions for patients. With this partnership, they aim to enhance the growth and global availability of a portfolio of life-changing pain management medicines, including treatments for opioid-induced constipation, breakthrough cancer pain, and osteoporosis.
How are key players in the opioid-induced constipation treatment market strengthening their market position?
Major companies operating in the opioid-induced constipation treatment market are Pfizer Inc., Merck & Co. Inc., Bayer AG, Sanofi S.A., AstraZeneca plc, Takeda Pharmaceutical Company Limited, Daiichi Sankyo Chemical Pharma Co. Ltd., Bausch Health Companies Inc., Boehringer Ingelheim International GmbH., Shionogi & Co. Ltd., Ono Pharmaceutical Co. Ltd., Dr. Reddy's Laboratories Ltd., Hikma Pharmaceuticals plc, Mundipharma International Limited, Lantheus Holdings Inc., Indivior plc, Mallinckrodt Pharmaceuticals, Collegium Pharmaceutical Inc., Ironwood Pharmaceuticals Inc., Cosmo Pharmaceuticals SA, Nektar Therapeutics, RedHill Biopharma Ltd., Theravance Biopharma Inc., Cumberland Pharmaceuticals Inc., Valinor Pharma LLC
Which geographic areas are contributing significantly to the growth of the opioid-induced constipation treatment sector?
North America was the largest region in the opioid-induced constipation treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the opioid-induced constipation treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
How Can Companies Use The Opioid-Induced Constipation Treatment Market Report to Drive Business Results?
This report provides actionable insights tailored for business use—not academic analysis. Companies can leverage the data to:
• Time market entry or expansion using growth forecasts and CAGR trends.
• Develop competitive products by tracking key technology shifts and user preferences.
• Tailor regional strategies with in-depth geographic data and local market dynamics.
• Benchmark and plan partnerships using competitive landscape insights.
Purchase The Report And Get A Swift Delivery:
Need Customized Data On Opioid-Induced Constipation Treatment Market?
For companies needing more tailored intelligence, The Business Research Company offers customized consulting and data services. Whether you're entering new regions, launching innovative products, or assessing M&A opportunities, our experts can develop actionable insights specific to your business objectives.
Request Customized Data:
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Comments
Post a Comment